Core Viewpoint - Genting Yongyao is making a strategic investment of $30.9 million in I-Mab, acquiring approximately 16.1% of the company's shares, thus becoming its largest shareholder. This investment aims to enhance the development of next-generation tumor immunotherapy pipelines globally [1][2][3]. Group 1: Investment Details - Genting Yongyao will invest $30.9 million (approximately HKD 242.6 million) in I-Mab, which will result in a total ownership of about 16.1% of I-Mab's shares [1][2]. - The investment will be made through the purchase of 15,846,154 American Depositary Shares (ADSs) at a price of $1.95 per share, contributing to a total fundraising of approximately $65 million by I-Mab [4][5]. - The investment will be classified as a non-current asset under the "Investments" section on Genting Yongyao's balance sheet, with subsequent fair value changes reflected in other comprehensive income [4]. Group 2: Clinical Development and Product Pipeline - I-Mab has recently presented promising results for Givastomig (Claudin 18.2 x 4-1BB bispecific antibody) at the 2025 ESMO GI conference, showing an objective response rate (ORR) of 83% in a phase 1b dose-escalation study for first-line gastric cancer treatment [1][5]. - I-Mab's differentiated 4-1BB receptor-targeting platform and bispecific antibody pipeline complement Genting Yongyao's AI+mRNA platform and autologous CAR-T platform, creating a new generation of tumor immunotherapy product matrix [1][3]. - The collaboration is expected to leverage both companies' strengths in clinical development and business expansion, particularly I-Mab's capabilities in the U.S. and Genting Yongyao's advantages in Asia [4].

Group 1 - The core point of the news is that CloudTop New Horizon (云顶新耀) announced an investment of $30.9 million in I-Mab, making it the largest shareholder with approximately 16.1% ownership after the transaction [2][3] - I-Mab is a global biotechnology company based in the United States, listed on NASDAQ, focusing on the development of precision immunotherapy drugs for cancer treatment [2] - I-Mab currently has three clinical development pipeline products, including two bispecific antibodies and one CD73 antibody, with a reported objective response rate (ORR) of 83% in a recent clinical trial for gastric cancer [2] Group 2 - CloudTop New Horizon's CEO stated that the strategic direction of the company aligns well with I-Mab's differentiated 4-1BB platform and bispecific antibody pipeline, which can create a new generation of tumor immunotherapy product matrix [3] - The investment is based on I-Mab's next-generation tumor immune product pipeline and its clinical development capabilities in the U.S., which complement CloudTop's strong presence in the Asian market [3] - The collaboration is expected to leverage both companies' expertise in clinical development and business expansion in China and globally, providing more breakthrough treatment options for cancer patients [3]

Group 1 - Company Gindalbie Metals announced the acquisition of 15.84 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million [1] - Following the acquisition, the company will hold a total of 15.84 million ADS and 6.08 million ordinary shares, representing about 16.1% of I-Mab's total issued share capital post-transaction [1] - The company focuses on innovative drug and vaccine research and development, with a strategic pipeline of promising clinical-stage products aimed at addressing unmet medical needs globally [1] Group 2 - I-Mab is a global biotechnology company headquartered in the United States, specializing in precision immuno-oncology drugs for cancer treatment [2] - I-Mab has three clinical-stage pipeline products, including Givastomig, Ragistomig, and Uliledlimab, which are designed to target specific cancer markers [2] - The board believes that the acquisition will enhance I-Mab's unique capabilities in clinical translation, particularly in the U.S., and complement the company's existing investments in mRNA cancer vaccines [2]

Group 1 - Company Gindalbie Metals Limited announced the subscription of 15.8462 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million [1] - After the subscription, the company will hold a total of 15.8462 million ADS and 6.0786 million ordinary shares, representing about 16.1% of I-Mab's total issued share capital post-transaction [1] - The company focuses on innovative drug and vaccine research and development, with a strategic pipeline of promising clinical-stage products and aims to address unmet medical needs globally [1] Group 2 - I-Mab is a global biotechnology company headquartered in the United States, specializing in precision immuno-oncology drugs for cancer treatment [2] - I-Mab has three clinical-stage pipeline products, including Givastomig, Ragistomig, and Uliledlimab, showcasing its unique capabilities in clinical translation [2] - The subscription is expected to create complementary and synergistic effects between I-Mab's strengths in the U.S. and the company's influence in the Asia-Pacific region, particularly in the area of mRNA cancer vaccines [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲 頂 新 耀 有 限 公 司 自願性公告 本公告由雲頂新耀有限公司（「本公司」）自願作出。 本 公 司 董 事（「 董 事 」）會（「 董 事 會 」）宣 佈 ， 於 2025 年 8 月 1 日 ， 本 公 司 認 購 I -Mab （「 I -M a b 」）（ 一 間 於 納 斯 達 克 全 球 市 場 上 市 之 公 司 ， 股 份 代 號 為「 IM AB 」）之 15,846,154股美國預託股份（「ADS」）（ 每十(10)股ADS相當於二十三(23)股普通股 ） （「認購事項」），每股ADS為1.95美元（ 相當於約每股ADS 15.3港元 ）。認購事項之 總代價為30.9百萬美元（ 相當於約242.6百萬港元 ）。認購事項完成後，本公司將合 共持有15,846,154股ADS ...

Group 1 - The company completed a placement and subscription agreement on July 30, 2025, successfully placing a total of 22,561,000 shares at a price of HKD 69.70 per share [1] - The company issued the subscribed shares on August 1, 2025, after all conditions of the subscription were met [1] Group 2 - The net proceeds from the subscription amount to approximately HKD 1,553.39 million [2] - The company plans to allocate the net proceeds as follows: 50% (approximately HKD 776.69 million) for global R&D of pipeline products, 40% (approximately HKD 621.36 million) for ongoing commercialization efforts, and 10% (approximately HKD 155.34 million) for working capital and general administrative purposes [2]

云顶新耀(01952)发布公告，根据配售及认购协议的条款及条件，配售事项已于2025年7月30日完成，其 中合共2256.1万股待售股份已由配售代理尽力成功配售予不少于六名承配人，每股待售股份的购买价为 69.70港元。 由于完成认购事项的所有条件已达成，故公司根据配售及认购协议的条款及条件于2025年8月1日按每股 认购股份69.70港元配发及发行2256.1万股认购股份予卖方。 ...

由于完成认购事项的所有条件已达成，故公司根据配售及认购协议的条款及条件于2025年8月1日按每股 认购股份69.70港元配发及发行2256.1万股认购股份予卖方。 智通财经APP讯，云顶新耀(01952)发布公告，根据配售及认购协议的条款及条件，配售事项已于2025年 7月30日完成，其中合共2256.1万股待售股份已由配售代理尽力成功配售予不少于六名承配人，每股待 售股份的购买价为69.70港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 雲頂新耀有限公司 呈交日期： 2025年8月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 01952 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該 等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國或在刊發或派發本公告可能屬違法的任何其他司法 管轄權區內刊發或派發。 本公告僅供參考之用，並不構成收購、購買或認購本公司任何證券之邀請或要約。 本公告並不構成在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公告所述證券 並無且將不會根據美國《1933年證券法》（「美國證券法」）登記，及不得在美國提呈或出售，除非根 據美國證券法作出登記或獲豁免或為毋須根據美國證券法作出登記之交易。本公司無意根據美國 證券法登記本公告內所述之任何證券或在美國進行證券之公開發售。 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲 頂 新 耀 有 限 公 司 完成根據一般授權配售現有股份及以先舊後新方式認購新股份 茲 提 述本 公 司 於2025 年 7 月25 日 就配 售 事 項 及認 購 事 項刊 發 之 公 ...